Document is current
Any future updates will be listed below
-
Authors
Tan, Yeh Fong https://orcid.org/0000-0003-3361-4300
Yeh, Chen-Yun https://orcid.org/0000-0003-1049-8052
Hsu, Sheng-Yun https://orcid.org/0009-0005-7926-6972
Lu, Chun-Hao https://orcid.org/0000-0001-7084-9374
Tsai, Ching-Hui https://orcid.org/0000-0003-0998-8230
Chiang, Pei-Chuan https://orcid.org/0009-0009-8057-4621
Weng, Hao-Jui https://orcid.org/0000-0002-7006-7599
Tsai, Tsen-Fang
Lee, Yungling Leo https://orcid.org/0000-0002-2234-9479
-
Funding
Funding for this research was provided by:
National Taiwan University Hospital (UN108-015)
National Taiwan University Hospital (UN110-032)
Academia Sinica (AS-BRPT-112-01)
Academia Sinica (AS-IDR-112-01)
- License Information
-
More Information
Article History
Received: 12 December 2024
Accepted: 29 August 2025
First Online: 29 September 2025
Competing interests
: T.F.T. has conducted clinical trials or received honoraria for serving as a consultant for AbbVie, AnaptysBio, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline-Stiefel, Janssen-Cilag, Leo-Pharma, Merck, Novartis, PharmaEssentia, Pfizer, Sanofi, Sun Pharma and UCB. The remaining authors state no competing interests.
